Progress and challenges towards targeted delivery of cancer therapeutics

Targeted delivery approaches for cancer therapeutics have shown a steep rise over the past few decades. However, compared to the plethora of successful pre-clinical studies, only 15 passively targeted nanocarriers (NCs) have been approved for clinical use and none of the actively targeted NCs have a...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenblum, Daniel, Joshi, Nitin, Tao, Wei, Karp, Jeffrey M., Peer, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897557/
https://www.ncbi.nlm.nih.gov/pubmed/29650952
http://dx.doi.org/10.1038/s41467-018-03705-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897557/
https://www.ncbi.nlm.nih.gov/pubmed/29650952
http://dx.doi.org/10.1038/s41467-018-03705-y

Ejemplares similares